The Trump administration is advancing federal support for psychedelic medicine through executive orders and cabinet-level advocacy. President Trump signed an executive order directing the federal government to study ibogaine, a psychedelic derived from an African shrub, as a potential treatment for post-traumatic stress disorder, traumatic brain injury, and opioid dependence in veterans. The order also directs the FDA and DEA to establish a pathway for eligible patients to access investigational psychedelic drugs, including psilocybin and ibogaine, under the Right to Try Act.
Secretary of Health and Human Services Robert F. Kennedy Jr. told podcast host Joe Rogan that the Trump administration is “very anxious” to allow psychedelic therapy “as quickly as possible.” Kennedy expressed confidence that psychedelic substances like psilocybin and MDMA will be made available in controlled settings for treating conditions such as post-traumatic stress disorder and depression. The U.S. Department of Veterans Affairs, Food and Drug Administration, and National Institutes of Health have all taken interest in advancing psychedelic medicine.
The executive order allocates at least $50 million from existing federal funds to support state programs advancing psychedelic drugs for serious mental illnesses. It also directs HHS, FDA, the VA, and private sector partners to increase clinical trial participation, data sharing, and real-world evidence generation for psychedelic drugs that have received Breakthrough Therapy designation. Additionally, once a Schedule I substance successfully completes Phase 3 trials for a serious mental health disorder, the attorney general is directed to initiate rescheduling review as quickly as practicable.
The order signals meaningful federal commitment, though important obstacles remain. Ibogaine and psilocybin remain Schedule I substances, and the legal and regulatory pathways to approval are complex. However, administrative support creates different conditions for petitions, rulemaking, and clinical trial approvals. Key developments to watch include how HHS handles the psilocybin rescheduling petition, how the FDA approaches applications for psychedelic-assisted therapies, whether the DEA signals willingness to revisit Schedule I designations, and whether private clinical trial efforts continue to expand.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://natlawreview.com/article/trump-administration-all-psychedelics